Toray Industries, Inc.

Mie Kaino

Hiroyuki Meguro

Kozue Takagaki

Hideki Inoue

Takehiro Takahashi

Yukihiro Nishio

Kenichi Hayashi

Tomohide Masuda

Keiichi Okimura

Takumi Aoki

Shinya Yokosaka

Yuko Kubota

Hideyuki Tsutsui

Yumiko Sekiya

Hiroe Hirokawa

Syuji Udagawa

Kazuya Osumi

Martial Vallet

Shinnosuke Hayashi

Masashi Yamamoto

Hideki Kawai

Noriyuki Hirano

Rie Sasaki

Naoyoshi Yamamoto

Ryutaro Suzuki

Sunao Hara

Tomofumi Ohyama

Takashi Nagahara

Tazuru Uchida

Yosuke Iura

Hiroaki Kaneko

Yutaka Nishimura

Takashi Nagahawa

A therapeutic agent or a preventive agent for alopecia areata has an ROR&#x3b3; antagonistic activity, and, there is a therapeutic agent or a preventive agent for alopecia areata, including a cyclic amine derivative typified by the following compound or a pharmacologically acceptable salt thereof as an active ingredient. 

Therapeutic agent or preventive agent for alopecia areata

A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof. 

Urea derivative and use therefor

A compound has retinoid-related orphan receptor &#x3b3; antagonist activity and shows a therapeutic effect or a preventive effect on autoimmune diseases such as multiple sclerosis or psoriasis or allergic diseases, including allergic dermatitis or the like, such as contact dermatitis or atopic dermatitis. The cyclic amine derivative is represented by the formula or a pharmacologically acceptable salt thereof. 

Cyclic amine derivative and medical use thereof

A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, Ris trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each Ris independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; Ris a hydrogen atom, halogen atom, C-Calkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or RO&#x2014;; and Ris phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R.

A method of treating or preventing multiple sclerosis includes administering a therapeutically effective amount of a cyclohexane derivative represented by Formula (I): wherein A is a substituent represented by Formula (IIa) or (IIb): Rand Rare each independently a hydrogen atom, chlorine atom, C-Chaloalkyl, C-Calkyl, C-Calkoxy, or cyano; Ris a hydrogen atom or chlorine atom; Ris a fluorine atom, hydroxymethyl, or hydroxyl; Rand Rare each independently a hydrogen atom, fluorine atom, C-Chaloalkyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, C-Calkoxy, hydroxyl, or C-Calkylcarbonyloxy, or optionally together form oxo; Rand Rare each independently a hydrogen atom or fluorine atom; Y is an oxygen atom or sulfur atom; and Z is a nitrogen atom or methine or a pharmaceutically acceptable salt thereof to a mammal.

Methods of treating or preventing multiple sclerosis

A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect. 

Therapeutic or prophylactic agent for allergic dermatitis

A 2,3-dihydro-1H-indene-2-yl urea represented by Formula (Ia) or a pharmaceutically acceptable salt thereof: 

[object Object]

A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects. 

Therapeutic or prophylactic agent for leukemia

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects. 

Therapeutic or prophylactic agent for multiple sclerosis

The compounds of the disclosure, for example, the compound represented by the formula: has excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo stability when administered orally in comparison with conventional compounds. That is, the compounds can be administered orally, and can have excellent therapeutic or prophylactic effect sustained for a longer period of time.

Glycine derivative and use thereof

Growing community of inventors

Kamakura, Japan

Mie Kaino